Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Conditions: Solid Tumor, Adult

Interventions: Biological: GAd-209-FSP low dose; Biological: MVA-209-FSP low dose; Biological: GAd-209-FSP high dose; Biological: MVA-209-FSP high dose; Biological: GAd20-209-FSP, RP2D; Biological: MVA-209-FSP, RP2D

Sponsors: Nouscom SRL

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 6, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments